Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals

URN to cite this document:: urn:nbn:de:bvb:355-epub-527492
DOI to cite this document:: 10.5283/epub.52749

Mader, Anna-Lena ; Tydykov, Leonid ; Glück, Vivian ; Bertok, Manuela ; Weidlich, Tanja ; Gottwald, Christine ; Stefl, Alexa ; Vogel, Matthias ; Plentz, Annelie ; Köstler, Josef ; Salzberger, Bernd ; Wenzel, Jürgen J.

; Niller, Hans Helmut ; Jantsch, Jonathan ; Wagner, Ralf ; Schmidt, Barbara ; Glück, Thomas ; Gessner, André ; Peterhoff, David

License: Creative Commons Attribution Non-commercial Share Alike 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 16 Aug 2022 14:17

Alternative links to fulltext:DOI Publisher Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

SARS-CoV-2 Omicron is the first pandemic variant of concern exhibiting an abrupt accumulation of mutations particularly in the receptor-binding domain that is a critical target of vaccination induced and therapeutic antibodies. Omicron's mutations did only marginally affect the binding of ACE2, and the two antibodies Sotrovimab and CR3022 but strongly impaired the binding of Casirivimab and ...